NEW YORK (GenomeWeb) – Muses Labs announced today that it has formed a partnership with Metabolon to research the metabolomics of pre- and early-symptomatic cognitive decline and Alzheimer's disease. 

Muses Labs currently markets a protocol called MEND for Alzheimer's disease, dementia, and related conditions. The methodology involves analyzing patients' genetic data and other medical information to identify the underlying pathways of their disorders and guide physician's treatment plans. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

Sponsored by

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.